Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

OBJECTIVE: Assessment of 12-month safety of ospemifene 60 mg/day for treatment of postmenopausal women with vulvar and vaginal atrophy (VVA). METHODS: In this 52-week, randomized, double-blind, placebo-controlled, parallel-group study, women 40–80 years with VVA and an intact uterus were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, S. R., Bachmann, G. A., Koninckx, P. R., Lin, V. H., Portman, D. J., Ylikorkala, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971738/
https://www.ncbi.nlm.nih.gov/pubmed/23984673
http://dx.doi.org/10.3109/13697137.2013.834493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971738/
https://www.ncbi.nlm.nih.gov/pubmed/23984673
http://dx.doi.org/10.3109/13697137.2013.834493

Ejemplares similares